Innovations in Prenatal Care
A History of Innovation
Since its inception, NTD Labs has demonstrated a history of innovation, beginning with its work in neural tube defect research and continuing to where it stands today, at the forefront of prenatal care and genetic screening.
| 1976 | NTD Labs founder J.N. Macri, Ph.D. introduces AFP screening for neural tube defects in the United States of America. |
| 1983 | NTD Labs is founded by Dr. Macri as a prenatal screening and research laboratory. |
| 1984 | Initial observations made on the association of low AFP and Down syndrome. |
| 1989 | Initial observations made on free Beta hCG as a biomarker for Down syndrome. |
| 1995 | NTD Labs introduces first trimester Down syndrome screening. |
| 2002 | Landmark NICHD study published that validates the advantages of the free Beta hCG/PAPP-A/NT protocol. |
| 2005 | Instant Risk Assessment program introduced. |
| 2005 | Fetal nasal bone assessment protocol introduced as part of the Down syndrome screening protocol. |
| 2006 | NTD Labs introduces web portal to facilitate Instant Risk Assessment reporting within the Down syndrome screening protocol. |
| 2006 | NTD Labs acquired by PerkinElmer. |
| 2009 | Cystic Fibrosis Carrier Testing launched by NTD Labs, from PerkinElmer. |